Investigators analyzed the immune-modulatory cancer vaccine IO102-IO103 plus pembrolizumab for PFS in patients with untreated advanced melanoma.

Initial CX-801 clinical data in advanced melanoma, both as monotherapy and in combination with KEYTRUDA, are expected by the end of 2026, with observed tolerability at doses surpassing the approved ...

Safety was described as manageable for both doublet and triplet regimens with no new signals, supporting feasibility of comprehensive pathway targeting in metastatic disease. Company plans include an ...

Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.

Versus Q4 2025’s data-centric call, Q1 2026 added a more execution-and-capital framing, with Chris Ogden emphasizing “projected cash runway to at least the second half of 2028,” supporting a sustained ...

Puma Biotechnology (NASDAQ:PBYI) reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX ...

Good morning. My name is David, and I'll be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions] I'd like to introduce Beth DelGiacco, Vice President ...

Unico Silver Ltd (ASX:USL, OTC:USLRF) has reported further high-grade gold-silver drill results from the Joaquin Project in ...

Detailed price information for Snowline Gold Corp (SGD-T) from The Globe and Mail including charting and trades.

Operator: Hello, everyone. Thank you for joining us, and welcome to the BlackRock TCP Capital Corp. Q1 2026 Earnings Call.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company') announced that the sNDA (the 'Application') for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also ...

(NASDAQ:ARGX) reported first-quarter 2026 results highlighting continued commercial growth for VYVGART and progress across ...